Literature DB >> 20838925

Acute phase expression pattern of ZnTs, LC3, and beclin-1 in rat Hippocampus and its regulation by 3-methyladenine following recurrent neonatal seizures.

Hong Ni1, Xing Feng, Yong Gong, Lu-Yang Tao, Xi-Ru Wu.   

Abstract

It has been reported that autophagy and zinc transporters (ZnTs) both play the key roles in excitotoxicity, which is associated with cognitive deficits following developmental seizures. However, the influence of autophagy on acute phase ZnTs expression has never been studied. The present study sought to investigate the contribution of an autophagy inhibitor (3-methyladenine, 3-MA) on the regulation of ZnTs, microtubule-associated protein 1A/1B light chain 3 (LC3), and beclin-1 expression in rat hippocampus following recurrent neonatal seizures. We examined the expression of ZnT1~ZnT3, LC3, and beclin-1 at 1.5, 3, 6, and 24 h after the last seizures using real-time RT-PCR and Western blot methods, respectively. The results showed that there were upregulated expressions of ZnT-1, ZnT-2, LC3, and beclin-1 of RS group. Pretreatment with 3-MA remarkably attenuated seizure-induced ZnT-1, ZnT-2, LC3, and beclin-1 increase. Additionally, linear correlations could be observed between LC3-Beclin1, LC3-ZnT-2, Beclin1-ZnT2, Beclin1-ZnT3, and among ZnT1~ZnT3 in control group, while the linear correlations could be observed between LC3-Beclin1, Beclin1-ZnT2, and Beclin1-ZnT3 in RS group. These results demonstrate, for the first time, that there exists an interaction of Zn(2+) with autophagic signals that are immediately activated in hippocampus after recurrent neonatal seizures, which might play a key role in neonatal seizure-induced excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20838925     DOI: 10.1007/s12011-010-8836-5

Source DB:  PubMed          Journal:  Biol Trace Elem Res        ISSN: 0163-4984            Impact factor:   3.738


  8 in total

1.  Long-term effects of recurrent neonatal seizures on neurobehavioral function and related gene expression and its intervention by inhibitor of cathepsin B.

Authors:  Hong Ni; Jian-Zhen Yan; Le-Ling Zhang; Xing Feng; Xi-Ru Wu
Journal:  Neurochem Res       Date:  2011-08-13       Impact factor: 3.996

2.  Dysregulation of zinc/lipid metabolism‑associated genes in the rat hippocampus and cerebral cortex in early adulthood following recurrent neonatal seizures.

Authors:  Zhen-Hong Li; Li-Li Li; Mei-Fang Jin; Xu-Qin Chen; Qi Sun; Hong Ni
Journal:  Mol Med Rep       Date:  2017-08-03       Impact factor: 2.952

Review 3.  The Effects of Leptin on Glial Cells in Neurological Diseases.

Authors:  Yuki Fujita; Toshihide Yamashita
Journal:  Front Neurosci       Date:  2019-08-07       Impact factor: 4.677

4.  Long-term expression of zinc transporters in hippocampus following penicillin-induced developmental seizures and its regulation by E-64d.

Authors:  Hong Ni; LE-Ling Zhang; Shou-Yun Ren; Bao-Liang Sun
Journal:  Exp Ther Med       Date:  2016-04-20       Impact factor: 2.447

5.  miR-96 attenuates status epilepticus-induced brain injury by directly targeting Atg7 and Atg16L1.

Authors:  Jing Gan; Qianyun Cai; Yi Qu; Fengyan Zhao; Chaomin Wan; Rong Luo; Dezhi Mu
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

6.  Leptin Maintained Zinc Homeostasis Against Glutamate-Induced Excitotoxicity by Preventing Mitophagy-Mediated Mitochondrial Activation in HT22 Hippocampal Neuronal Cells.

Authors:  Mei-Fang Jin; Hong Ni; Li-Li Li
Journal:  Front Neurol       Date:  2018-05-09       Impact factor: 4.003

Review 7.  Insights into Potential Targets for Therapeutic Intervention in Epilepsy.

Authors:  Cecilia Zavala-Tecuapetla; Manola Cuellar-Herrera; Hiram Luna-Munguia
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

8.  Editorial: Endocrine Modulators of Neurological Processes: Potential Treatment Targets of Pediatric Neurological Diseases.

Authors:  Hong Ni; Giuseppe Biagini; Dinesh Upadhya; Alessandro Capuano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-18       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.